CA3046911A1 - Electronically-active cannabinoids - Google Patents

Abstract

An animal's nervous system consists of individual neural cells (neurons), support cells and support structures. Neurons are the fundamental units of the brain and nervous system, the cells responsible for receiving sensory input from the external world, for sending motor commands to our muscles, and for transforming and relaying the electrical signals at every step in between. Neurons communicate with each other and the outside world through a combination of electrical and chemical signals, both within and external to the neuron.
The central hub or soma of a neuron is connected to other neurons via transmitting arms or extensions (axons) of the first neuron, and receiving arms or extensions (dendrites) of the second neuron. Signals to be transmitted from one neuron to another travel electrically from the central soma region of the neuron, inside the connected axon to the end of the axon.
At the end of an axon, an axon terminal or interface junction exists connecting the axon of the first neuron to the dendrite of the second. The electrical signal, having passed from the first's axon to the second's dendrite, then continues electrically inside the dendrite to the central soma of the second neuron. Signals flow by electrical processes within the neutron including electrotonic motion potentials and concentration-gradient action motion potentials.

Description

PATENT DESCRIPTION
Electronically-active Cannabinoids SPECIFICATION
Description Cannabidiol (CBD) is a phytocannabinoid discovered in 1940. It is one of some 113 identified cannabinoids in cannabis plants and accounts for up to 40% of the plant's extract.[7] In 2018, clinical research on cannabidiol included preliminary studies of anxiety, cognition, movement disorders, and pain.[8]
Cannabidiol can be taken into the body in multiple ways, including by inhalation of cannabis smoke or vapor, as an aerosol spray into the cheek, and by mouth. It may be supplied as CBD oil containing only CBD as the active ingredient (no included tetrahydrocannabinol [THC] or terpenes), a full-plant CBD-dominant hemp extract oil, capsules, dried cannabis, or as a prescription liquid solution.[2] CBD does not have the same psychoactivity as THC,[9][10] and may affect the actions of THC.[7][8][9][11] As of 2018, the mechanism of action for its biological effects has not been determined .[8}[9]
=õH OH
HO
Scheme 1 The CBD molecule PEG-6-PPG-6-PEG dimethacrylate ("PPPDI") is a nontoxic copolymer that displays strong quantum electron tunnelling properties.

011),..1,=õ.õ0 113 1 C113 OI 011)c NEt--z Scheme 2 PEG-b-PPG-b-PEG PEG-b-PPG-b-PEG dimethacrylate PEG-Z>-PPG-Z>-PEG dimethacrylate was synthesized as follows. PEG-Z>-PPG-Z>-PEG (Mn-8,400 g/mol) (168 g, 0.020 mol) was transferred into a three-neck round bottom flask and dissolved in 100 mL anhydrous THF.
Then, triethylamine (4.86 g, 0.048 mol) was added to the solution at 0 C.
Methacryloyl chloride (5.00 g, 0.048 mol) was dissolved in 24 mL
anhydrous THF and added dropwise to the PEG-Z>-PPG-Z>-PEG solution by dropping funnel under nitrogen atmosphere. Hereafter, the mixture was stirred for 24 h at room temperature to complete the reaction. Vacuum filtration later was used to separate the insoluble triethylamine hydrochloride salts from the resultant mixture. The filtrate was passed through the column filled with neutral alumina to remove the excess residue of triethylamine. Finally, solvent was evaporated and the purified polymer was dried further in a vacuum oven at room temperature for 24 h. The synthesis pathway for the preparation of PEG-&-PPG-&-PEG
dimethacrylate is shown in Scheme 2.
[00128]IHNMR (500 MHz, CDC13, 6 (ppm)): 6.00- 5.50 (two set of m, -C=CH2, vinyl bonds), 3.70-3.38 (m, -0-CH2- and -0-CH< PEG and PPG
chains), 1.11 (s, -CH3, PPG chains). IR (cm"): 2800- 2900 (str, asym and sym -CH2- and -CH3 stretches), 1720 (wk, >C=0 stretch), 1270-1460 (med, -CH2- and -CH3 bending), 1090 (str, -C-0- stretch).
A block copolymer PEG-&-PPG-&-PEG dimethacrylate (PPPDI) was synthesized to minimize the bond resistance between two co-operating bond surfaces, and hence improve the signal transmission in between. It was found that the resistance of this insulating polymer dramatically decreases to around 60 0 when the film thickness reaches 35.7 nm at 298 K, which greatly grants the usage of this material in electrically active bonds. Moreover, the high conductivity of ultrathin PPPDI film is ascribed to the electrons emitted by high applied electric field. A non-Ohmic conductivity behavior has been observed on thin PPPDI film in the thickness range between 35.7 and 141.2 nm regardless of measuring temperature. Study about the effects of the film thickness and measuring temperature on the current density-electric field characteristics has revealed that the logarithm of the current density is linearly dependent on the square root of electric field in the non-Ohmic region for each thickness and temperature. Also, this linearity is independent of the thickness value in the studied range. Additionally, this material exhibited higher conductivity at higher temperature, arising from the higher thermal 1 energy of electrons. A
comparison between the coefficient value of log(/) vs. Ez from experimental results and theoretically derived values from Schottky and Poole-Frenkel emission indicated that the conductivity of PPPDI is more likely to be Schottky emission.
The linear relationship between log(") and 1/T further confirmed the occurrence of Schottky emission in thin PPPDI films.
CBD-PPPDI-CBD molecule ("CPC") In this invention CBD is combined chemically with PPPDI to create an end-to-end polymer chain of shape CBD-PPPDI-CPD (`CPC", "QCBD"). In the synapse, the CPC molecular shape is such that the electrical field produced by a positive-charge electrotonic potential or concentration-gradient action potential motion of the ions inside the axon combined with the CBD molecule's affinity for the receptors of the dendrite cause the CPC
molecule to move towards the receptor. The motion causes the copolymer to actively rotate and align CBD-end forward. The CBD end then embeds in the dendrite receptor where it elucidates the normal anandamide chemical response of the dendrite. The PPPDI mid-section of the CPC
molecule is effectively suspended between the axon and the dendrite such that it can utilize quantum electron tunnelling processes in the synapse.
Through the action of quantum electron tunnelling, the electrical charge pulse carried internally in the ions of the axon is transmitted electrically to the ions of the dendrite by of the presence of the PPPDI molecular section.
Thus a continuous electrical path is established between the axon and the dendrite. Electrons in this electrical path move at close to the speed of light, while the standard chemical response is approximately 100 m/s.
Thus several effects occur:

1. Introduction of an active electrical signal between axon and dendrite, translating to stronger inter-neural communication.

2. increased chemical signal between axon and dendrite owing to the presence of CBD in the dendrite receptors.

3. Active field-potential steering of the molecule. Thus CPC acts effectively as a molecular-sized controllable machine or "nanobot".

4. Exposure to the increased signal strengths causes the axon/synapse/dendrite pathway to be strengthened beyond previous levels through the nervous system's physiological response, strengthening the pathway. This results in enhanced neural connection even after the CPC
molecule has been removed from the synapse by the normal flushing processes of the physiology. The effects thus are long-lasting or may even become permanent.
Embodiments 1. A first embodiment provides a chemical bond comprising: a first bond surface; a second bond surface; and a coating dispersed on at least one of the first or second bond surfaces, where the coating includes the cured product of a telechelic polypropylene glycol-polyethylene glycol multi-block polymer.
2. A second embodiment provides a chemical bond as in the preceding embodiment, where telechelic polypropylene glycol-polyethylene glycol multi-block polymer is selected from the group consisting of diacrylate polypropylene glycol-block- polyethylene glycols, dimethacrylate polypropylene glycol-block-polyethylene glycols, diacrylate polypropylene glycol-block-polyethylene glycol-block-polypropylene glycols, dimethacrylate polypropylene glycol-block-polyethylene glycol-block-polypropylene glycols, diacrylate polyethylene glycol-block-polypropylene glycol-block-polyethylene glycols, dimethacrylate polyethylene glycol-block-polypropylene glycol-block- polyethylene glycols, diacrylate polypropylene glycol-block-polyethylene glycol-block- polypropylene glycol-block-polyethylene glycols, dimethacrylate polypropylene glycol- block-polyethylene glycol-block-polypropylene glycol-block-polyethylene glycols, diacrylate polyethylene glycol-block-polypropylene glycol-block-polyethylene glycol- block-polypropylene glycols, dimethacrylate polyethylene glycol-block-polypropylene glycol-block-polyethylene glycol-block-polypropylene glycols, and combinations thereof.

3. A third embodiment provides a chemical bond as in any preceding embodiments, where the telechelic polypropylene glycol¨polyethylene glycol multi-block polymer is defined by the formula:
O cH3 cH3 -x - z -"v -where each R1 is a hydrogen or a methyl group, x is from about 5 to about 30 y is from about 5 to about 30, and z is from about 5 to about 30.
4. A fourth embodiment provides a chemical bond as in any preceding embodiments, where the telechelic polypropylene glycol¨polyethylene glycol multi-block polymer is defined by the formula:
o _ _ _ _ -x - CH3 -z where each R1 is a hydrogen or a methyl group, x is from about 5 to about 30 y is from about 5 to about 30, and z is from about 5 to about 30.

5. A fifth embodiment provides a chemical bond as in any preceding embodiments, where the coating further includes the cured product of a reactive diluent.

6. A sixth embodiment provides a chemical bond as in any preceding embodiments, where the reactive diluent is a telechelic polyethylene glycol oligomers or a mono-functional polyethylene glycol oligomers.

7. A seventh embodiment provides a chemical bond as in any preceding embodiments, where the reactive diluent is a poly(ethylene glycol) diacrylate or poly(ethylene glycol) dimethacrylate defined by the following formula:

"%%#/%4' *" R1 n where each R1 is a hydrogen or a methyl group and n is from about 5 to about 9.

8. An eighth embodiment provides a chemical bond as in any preceding embodiments, where the reactive diluent is a poly(ethylene glycol) methyl ether acrylate or poly(ethylene glycol) methyl ether methacrylate defined by the following formula:

R1,4õs60,41rell 0.00.00000"*%%%4*%44,400/00Ø4%
AIM INN&
where R.1 is a hydrogen or a methyl group and n is from about 5 to about

9.
9. A ninth embodiment provides a chemical bond as in any of the preceding embodiments, where the coating further includes a wetting agent.

10. A tenth embodiment provides a chemical bond as in any of the preceding embodiments, where the coating further includes a photoinitiator.

11. An eleventh embodiment provides a chemical bond as in any of the preceding embodiments, where the coating is a gel.

12. A twelfth embodiment provides a chemical bond as in any of the preceding embodiments, where the telechelic polypropylene glycol-block-polyethylene glycol-block- polypropylene glycol polymer has a number average molecular weight of about 2500 to about 3000 g/mol.

13. A thirteenth embodiment provides a chemical bond as in any of the preceding embodiments, where the coating has a thickness from about mm pal to about 3000 nm.

14. A fourteenth embodiment provides a chemical bond as in any of the preceding embodiments, where the coating is self-healing.

15. A fifteenth embodiment provides a chemical bond as in any of the preceding embodiments, where the first bond surface and the second bond surface are each independently made from a metal selected from gold, silver, copper, and combinations thereof.

16. A sixteenth embodiment provides a chemical bond as in any of the preceding embodiments, where the electrical bond is selected from electrical connectors, relays, switches, potentiometers, and faders.

17. A seventeenth embodiment provides a method of stabilizing a chemical bond comprising: providing a chemical bond that includes a first bond surface and a second bond surface; a coating at least one of the first or second bond surfaces with a curable chemical composition that includes a telechelic polypropylene glycol¨ polyethylene glycol multi-block polymer;
and curing the curable chemical composition.

18. An eighteenth embodiment provides a method as in any of the preceding embodiments, where the curable chemical composition includes a photoiniator, and the step of curing the curable chemical composition is performed by irradiating the curable chemical composition with UV light.

19. A nineteenth embodiment provides a method as in any of the preceding embodiments, where the telechelic polypropylene glycol¨polyethylene glycol multi-block polymer is selected from the group consisting of diacrylate polypropylene glycol-block- polyethylene glycols, dimethacrylate polypropylene glycol-block-polyethylene glycols, diacrylate polypropylene glycol-block-polyethylene glycol-block-polypropylene glycols, dimethacrylate polypropylene glycol-block-polyethylene glycol-block-polypropylene glycols, diacrylate polyethylene glycol-block-polypropylene glycol-block-polyethylene glycols, dimethacrylate polyethylene glycol-block-polypropylene glycol-block- polyethylene glycols, diacrylate polypropylene glycol-block-polyethylene glycol-block- polypropylene glycol-block-polyethylene glycols, dimethacrylate polypropylene glycol- block-polyethylene glycol-block-polypropylene glycol-block-polyethylene glycols, diacrylate polyethylene glycol-block-polypropylene glycol-block-polyethylene glycol- block-polypropylene glycols, dimethacrylate polyethylene glycol-block-polypropylene glycol-block-polyethylene glycol-block-polypropylene glycols, and combinations thereof.

20. A twentieth embodiment provides a method as in any of the preceding embodiments, where the telechelic polypropylene glycol¨polyethylene glycol multi-block polymer is defined by the formula:

-z where each R1 is a hydrogen or a methyl group, x is from about 5 to about 30 y is from about 5 to about 30, and z is from about 5 to about 30.

21. A twenty-first embodiment provides a method as in any of the preceding embodiments, where the telechelic polypropylene glycol¨
polyethylene glycol multi-block polymer is defined by the formula:

_ _ -x - CH3 - -Y
Z o where each R1 is a hydrogen or a methyl group, x is from about 5 to about 30 y is from about 5 to about 30, and z is from about 5 to about 30.

22. A twenty-second embodiment provides a method as in any of the preceding embodiments, where the curable chemical composition further includes a reactive diluent.

23. A twenty-third embodiment provides a method as in any of the preceding embodiments, where the reactive diluent is a telechelic polyethylene glycol oligomers or a mono-functional polyethylene glycol oligomers.

24. A twenty-fourth embodiment provides a method as in any of the preceding embodiments, where the reactive diluent is a poly(ethylene glycol) diacrylate or poly(ethylene glycol) dimethacrylate defined by the following formula:

n where each R1 is a hydrogen or a methyl group and n is from about 5 to about 9.

25. A twenty-fifth embodiment provides a method as in any of the preceding embodiments, where the reactive diluent is a poly(ethylene glycol) methyl ether acrylate or poly(ethylene glycol) methyl ether methacrylate defined by the following formula:
0 ¨ ¨
RI 4Ø00.00"=%%%%%440.00000,0fts..4%.

n . .......
where R.1 is a hydrogen or a methyl group and n is from about 5 to about 9.

26. A twenty-sixth embodiment provides a method as in any of the preceding embodiments, where the curable chemical composition further includes a wetting agent.

27. A twenty-seventh embodiment provides a method as in any of the preceding embodiments, where the curable chemical composition is solvent free or essentially solvent free.

28. A twenty-eighth embodiment provides a method as in any of the preceding embodiments, where the step of curing the curable chemical composition results in a cured coating composition in the form of a gel.
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
1. According to one or more embodiments, a stabilized electrical bond may be prepared by mating a chemical bond surface with a telechelic polypropylene glycol-polyethylene glycol multi-block polymer and then curing the telechelic polypropylene glycol¨polyethylene glycol multi-block polymer. Advantageously, it has been found that the stabilized electrical bonds exhibit improved performance. For the purpose of the present specification, the telechelic polypropylene glycol¨polyethylene glycol multi-block polymer may be referred to as the multi-block polymer.
2. As those skilled in the art will appreciate, the chemical bond includes two mating surfaces comprised of a quantum electron tunnelling material and the cannabinoid molecule. The two surfaces are each generally referred in the art as bonds, and for the purposes of this disclosure, each bond, or surface made of a quantum electron tunnelling conductive material in a chemical bond with a cannabinoid may be referred to as a bond surface.
3. The two bond surfaces in a chemical bond function co-operatively. In the presence of an ionic electrical field an electrical current may be passed by quantum electron tunnelling from the first to trigger the second ionic field.
4. Any electrical bond may be stabilized using the telechelic polypropylene glycol¨polyethylene glycol multi-block polymer.
5. In one or more embodiments, a stabilized electrical bond may be prepared by providing a chemical bond that includes a first bond surface and second bond surface, mating at least one of the first or second bond surfaces with a curable chemical composition, and then curing the curable chemical composition.
6. In one or more embodiments, the curable chemical composition includes a telechelic polypropylene glycol¨polyethylene glycol multi-block polymer.
The telechelic polypropylene glycol-polyethylene glycol multi-block polymer has two reactive end groups capable of reacting or undergoing polymerization when the curable chemical composition is cured to produce a crosslinked polymer. In one or more embodiments, the reactive end groups of the telechelic polypropylene glycol- polyethylene glycol multi-block polymer are acrylate functional groups or methacrylate functional groups.
7. In one or more embodiments, the telechelic polypropylene glycol-polyethylene glycol multi-block polymer may be characterized by its number average molar mass (Mn). In one or more embodiments, the number average molar mass of the telechelic polypropylene glycol¨
polyethylene glycol multi-block polymer is at least 2000 g/mol, in other embodiments at least 2200 g/mol, in other embodiments at least 2400 g/mol, in other embodiments at least 2500 g/mol, and in other embodiments at least 2600 g/mol.
8. In one or more embodiments, the number average molar mass of the telechelic polypropylene glycol-polyethylene glycol multi-block polymer is at most 2900 g/mol, in other embodiments at most 3000 g/mol, in other embodiments at most 3100 g/mol, in other embodiments at most 3200 g/mol, and in other embodiments at most 3300 g/mol. In one or more embodiments, the number average molar mass of the telechelic polypropylene glycol¨polyethylene glycol multi-block polymer is from about 2000 g/mol to about 3300 g/mol, in other embodiments from about 2200 g/mol to about 3200 g/mol, in other embodiments from about 2400 g/mol to about 3100 g/mol, in other embodiments from about 2500 g/mol to about 3000 g/mol, and in other embodiments from about 2600 g/mol to about 2900 g/mol.
9. In one or more embodiments, the telechelic polypropylene glycol-polyethylene glycol multi-block polymer may have two or more alternating blocks propylene glycol repeating units and polyethylene glycol repeating units. In one or more emodiments, the telechelic polypropylene glycol¨
polyethylene glycol multi-block polymer may have from about 2 to about blocks.
10. In one or embodiments, the telechelic polypropylene glycol-polyethylene glycol multi-block polymer may be a di-block copolymer represented by the formula: A- B, where A and B are different polymer blocks selected from polypropylene glycol or polyethylene glycol.
11. In one or embodiments, the telechelic polypropylene glycol-polyethylene glycol multi-block polymer may be a tri-block copolymer represented by the formula: A-B-A, where A and B are different polymer blocks selected from polypropylene glycol or polyethylene glycol.
12. In one or embodiments, the telechelic polypropylene glycol- -polyethylene glycol multi-block polymer may be a tetra-block copolymer represented by the formula: A-B-A-B, where A and B are different polymer blocks selected from polypropylene glycol or polyethylene glycol.

:einiwoj. 6u!monol aql Aq paupp aq Aew JewAnd Noon!linw aql looAP aualAdalclAnd -Noon-noA16 auelAgleAlod-Noon-looAp auelAdadAnd aielkoeinaw!P
e JO JawAnd looA16 aualAdoiclAnd-Noon-noAP aualfteAnd -Noon-100A16 auelAdoiclAnd eieliruoep e s! JawAnd Noolcl-RInw looAp aualAineAlod -100AI6 aualAdoiclAnd opqoalal ail waqm `sluaw!poqwe 8JOW JO auo u! -91.
-slooAlb aualAdoiclAiod-Noon-noAP auelAtuaAnd-Noon-p3A0 auelAdanAnd -Noon-noAp aueifteAnd aleikoeqiewp pue `sio3A0 aualAdaidAnd -Noon-1 3A6 aualAwAnd-Noon-poAP aualAdoiclAnd-Noon-109A16 auelAineAnd alelAioeup `snoA18 auelfteApd-Noon-p3A15 auelAdoiclAnd -Noon-1 0A6 euelAinaAnd -Noon-noAP auelAdoiclAnd aleikoeinew!P
`sio3A15 aualkneApd-Noon-looAP auelAdaidAnd-Noon-100A16 aualfteAnd-Noon-noAp auelAdoiclAnd aleikoep `snoAp aualAinaAnd -Noon-poAP euelAdoxIAnd-Noon-p3A0 euelAilleAnd eielkoeinewp `sio3A15 auelA1neAnd-Noon-p3A6 auelAdoiclApd-Noon-103A16 auelfteAnd aleikoello `slooAP auelAdoiclAiod-Noon-noAp aualfteAnd -Noon-n3A0 auelAdaidAnd eleikoeqlemp `slooAP aualAdoiclAnd -Noon-103A6 auelfteAnd-Noon-poAP auelAdoiclAnd aleIA.19e!P
`snoAP auelfteAlod-Noon-noAP auelAdadAnd eleifuoeqlaw!13 `s100A16 aualAqiaAnd-Noon-looAP aualAdadAnd alelkoep apnpu! JawAnd )1001q 111nw 103A0 auelfteAlocl-p3A0 euelAdoiclAiod D01430101 Aipenwax3 '91.
-JawAnd Noon-RInw noAP auefteAnd-looAp aualAdoiclAnd awl/Wallow e se ol pauelai aq Aew JawAnd Noon-RInw 100/16 auefteAlocl-n3A15 auelAdadAnd oueqoalel aqi `sdnoi6 aleikoeinaw we Jew/clod Noon-RInw 100A16 auelfteAnd-p3A0 aualAdoiclAnd opaqoalei an io sdnaP leuoRouni anRoew aqi &lawn `sluaw!poqwe &IOW JO auo ul 171.
-JawAnd Noolcl-RInw 100/16 aualftaApd-looAp aualAdoiclAnd aleiAnep e se ol panalw aq Aew JawAnd NooIchilnw 100A0 auelAtilaAlod-103A0 aualAdaidAnd 3!!aqoalei ail `sdnok alelkoe OR
Jew/clod Noonlilnw MAO aualfteAlocl-p3A0 auelAdoiclAnd onaqoalal aqi lo sdnalb ieuoRouni eApew aql waqm twaumpoqwe wow Jo auo u! -C1.

- z -x -y where each R1 is a hydrogen or a methyl group, x is from about 5 to about 30 y is from about 5 to about 30, and z is from about 5 to about 30. In one or more embodiments, x may be from about 7 to 25 in other embodiments from about 10 to 20, and in other embodiments from about 12 to 15. In one or more embodiments, y may be from about 7 to 25 in other embodiments from about 10 to 20, and in other embodiments from about 12 to 15.
17. In one or more embodiments, z may be from about 7 to 25 in other embodiments from about 10 to 20, and in other embodiments from about 12 to 15.
18. In one or more embodiments, where the telechelic polypropylene glycol¨ polyethylene glycol multi-block polymer is a diacrylate polyethylene glycol-block- polypropylene glycol-block-polyethylene glycol polymer or a dimethacrylate polyethylene glycol-block-polypropylene glycol-block-polyethylene glycol polymer the multiblock polymer may be defined by the following formula:
_ _ _ _ o -x CH3 -y - -z Where each R1 is a hydrogen or a methyl group, x is from about 5 to about 30 y is from about 5 to about 30, and z is from about 5 to about 30. In one or more embodiments, x may be from about 7 to 25 in other embodiments from about 10 to 20, and in other embodiments from about 12 to 15. In one or more embodiments, y may be from about 7 to 25 in other embodiments from about 10 to 20, and in other embodiments from about 12 to 15. In one or more embodiments, z may be from about 7 to 25 in other embodiments from about 10 to 20, and in other embodiments from about 12 to 15.

19. In one or more embodiments, the entirely of the curable chemical composition may be telechelic polypropylene glycol¨polyethylene glycol multi-block polymer. In other embodiments, the curable chemical composition may include other components such as, reactive diluents, initiators (such as photoinitators), wetting agents, and combinations thereof.
20. In one or more embodiments, the curable chemical composition may be characterized by the percentage of the telechelic polypropylene glycol-polyethylene glycol multi-block polymer in the curable chemical composition.
21. In one or more embodiment, the curable chemical composition is at least 25% in other embodiments at least 30%, in other embodiments at least 35%, and in other embodiments at least 40% by weight telechelic polypropylene glycol¨polyethylene glycol multi-block polymer.
22. In one or more embodiments the curable chemical composition is at most 95%, in other embodiments at most 90%, in other embodiments at most 75%, in other embodiments at most 70%, in other embodiments at most 65%, and in other embodiments at most 60% by weight telechelic polypropylene glycol¨polyethylene glycol multi-block polymer. In one or more embodiment, the curable chemical composition is from about 25% to about 75%, in other embodiments from about 30% to about 70%, in other embodiments from about 35% to about 65%, and in other embodiments from about 40% to about 60% by weight telechelic polypropylene glycol-polyethylene glycol multi-block polymer.
23. In one or more embodiments, the curable chemical composition includes a reactive diluent. It has been found that when certain reactive diluents are included in the curable chemical composition they may be used to help control the hardness or softness the resultant cured coating.
Suitable reactive diluents for adjusting the hardness of the cured coating include, but are not limited to telechelic polyethylene glycol oligomers and mono- functional polyethylene glycol oligomers.

24. In one or more embodiments, the telechelic polyethylene glycol oligomer or mono-functional polyethylene glycol oligomer may be characterized by its number average molar mass (Mn).
25. In one or more embodiments, the number average molar mass of the telechelic polyethylene glycol oligomer or mono-functional polyethylene glycol oligomer is at least 250 g/mol in other embodiments at least 300g/mol and in other embodiments at least 350 g/mol.
26. In one or more embodiments, the number average molar mass of the telechelic polyethylene glycol oligomer or mono-functional polyethylene glycol oligomer is at most 900 g/mol in other embodiments at most 700g/mol and in other embodiments at most 500 g/mol.
27. In one or more embodiments, the number average molar mass of the telechelic polyethylene glycol oligomer or mono-functional polyethylene glycol oligomer is from about 250 g/mol to about 900 g/mol, in other embodiments from about 300 g/mol to about 700 g/mol, and in other embodiments from 350 g/mol to about 500 g/mol, 28. In one or more embodiments, where the reactive functional groups of the telechelic polyethylene glycol oligomer are acrylate groups, the telechelic polyethylene glycol oligomer may be referred to as a poly(ethylene glycol) diacrylate.

29. n one or more embodiments, where the reactive functional groups of the telechelic polyethylene glycol oligomer are methacrylate groups, the telechelic polyethylene glycol oligomer may be referred to as a poly(ethylene glycol) dimethacrylate.

30. In one or more embodiments, where the reactive functional group of the mono-functional polyethylene glycol oligomer is a methacrylate groups, the mono-functional polyethylene glycol oligomer may be referred to as a poly(ethylene glycol) methyl ether acrylate.

31. In one or more embodiments, where the reactive functional group of the mono-functional polyethylene glycol oligomer is an acrylate groups, the mono-functional polyethylene glycol oligomer may be referred to as a poly(ethylene glycol) methyl ether methacrylate.

32. In one or more embodiments, the poly(ethylene glycol) diacrylate or poly(ethylene glycol) dimethacrylate may be defined by the following formula 0 **% -R11. .
_no where each R1 is a hydrogen or a methyl group and n is from about 4 to about 10.

33. In one or more embodiments, n may be from about 5 to 9, and in other embodiments from about 6 to about 7.

34. In one or more embodiments, the poly(ethylene glycol) methyl ether acrylate or poly(ethylene glycol) methyl ether methacrylate may be defined by the following formula R
O
where R.1 is a hydrogen or a methyl group and n is from about 4 to about 10.

35. In one or more embodiments, n may be from about 5 to 9, and in other embodiments from about 6 to about 7.

36. In one or more embodiments, the curable chemical composition may be characterized by the percentage of the reactive diluent in the curable chemical composition.

37. In one or more embodiment, the curable chemical composition is at least 25% in other embodiments at least 30%, in other embodiments at least 35%, and in other embodiments at least 40% by weight reactive diluent.

38. In one or more embodiments the curable chemical composition is at most 95%, in other embodiments at most 90%, in other embodiments at most 75%, in other embodiments at most 70%, in other embodiments at most 65%, and in other embodiments at most 60% by weight reactive diluent.

39. In one or more embodiment, the curable chemical composition is from about 25% to about 75%, in other embodiments from about 30% to about 70%, in other embodiments from about 35% to about 65%, and in other embodiments from about 40% to about 60% by weight reactive diluent.

40. In one or more embodiments, the curable chemical composition includes a wetting agent. It has been found that a wetting agent may be used in the curable composition to lower the surface tension of the curable composition and thus allow it to spread more easily on the bond surfaces.

41. In one or more embodiments, the wetting agent may be a silicone-containing wetting agent. Suitable silicone-containing wetting agents include polyether modified polydimethylsiloxanes such as BYK-333, available from BYK Additives & Instruments.

42. In one or more embodiments, the curable chemical composition may be characterized by the percentage of the wetting agent in the curable chemical composition.

43. In one or more embodiment, the curable chemical composition is at least 0.25% in other embodiments at least 0.30%, in other embodiments at least 0.35%, and in other embodiments at least 0.40% by weight wetting agent. In one or more embodiment, the curable chemical composition is at most 0.75%, in other embodiments at most 0.70%, in other embodiments at most 0.65%, and in other embodiments at most 0.60% by weight wetting agent. In one or more embodiment, the curable chemical composition is from about 0.25% to about 0.75%, in other embodiments from about 0.30%
to about 0.70%, in other embodiments from about 0.35% to about 0.65%, and in other embodiments from about 0.40% to about 0.60% by weight wetting agent.

44. In one or more embodiment the curable chemical composition may be cured through UV light. In these or other embodiments, the curable chemical composition may include a photoinitiator. Exemplary photoinitiators include 2-hydroxy-2- methylpropiophenone.

45. In one or more embodiments, the curable chemical composition may be characterized by the percentage of the photoinitiator in the curable chemical composition. In one or more embodiment, the curable chemical composition is at least 0.3%, in other embodiments at least 0.5%, and in other embodiments at least 0.7% by weight photoinitiator.

46. In one or more embodiment, the curable chemical composition is at most 3%, in other embodiments at most 2%, and in other embodiments at most 1 /(3 by weight photoinitiator.

47. In one or more embodiment, the curable chemical composition is from about 0.3% to about 3%, in other embodiments from about 0.5% to about 2%, and in other embodiments from about 0.7%to about 1% by weight photoinitiator.

48. In one or more embodiments, the curable chemical composition is essentially solvent free. In these or other embodiments, the curable chemical composition does not include a volatile organic compounds.

49. In one or more embodiments, the curable chemical composition includes less than 10% solvent, in other embodiments less than 5%
solvent, in other embodiments less than 3% solvent, and in other embodiments less than 163/0 solvent by weight.

50. In one or more embodiments, the curable chemical composition is solvent free.

51. In one or more embodiments, a method of stabilizing a chemical bond may include providing a chemical bond that includes a first bond surface and second bond surface, coating at least one of the first or second bond surfaces with the curable chemical composition; and then curing the curable chemical composition.

52. In one or more embodiments, one of the first or second bond surfaces is coated with the curable chemical composition. In other embodiments, both of the first and second bond surfaces are coated with the curable chemical composition.

53. The curable chemical composition may be coated onto a bond surface by various methods. Suitable methods for coating the curable chemical composition include flow coating and spin coating.

54. As noted above, flow coating may be used to coat the curable chemical composition onto a bond surface include flow coating. Flow coating has advantageously been found to provide a curable composition with a uniform thickness. In these embodiments, the flow coating device includes a knife blade secured at fixed distance away from the bond surface. A
small amount of the curable chemical composition is deposited or wicked between the bond surface and the knife blade. The blade or bond surface is then moved relative to each other to produce a thin coating with desired thickness. The flow coating process is considered as a result of the competition between the capillary forces holding the curable composition between the knife blade and the bond surface and the frictional drag exerted on that same curable composition when the blade (or bond surface) is pulled away.

55. The curable chemical composition may be cured by various methods suitable for reacting the reactive functional groups of the telechelic polypropylene glycol¨ polyethylene glycol multi-block polymer (and optionally any reactive diluents).

56. In one or more embodiments, the curable chemical composition may be partially cured prior to coating. In these or other embodiments, the coating is cured to an extent that allow coating to still be coated onto a bond and then curing is completed after the partially cured coating is applied to the bond.

57. In one or more embodiments, where the telechelic polypropylene glycol¨ polyethylene glycol multi-block polymer includes methacrylate or acrylate functional groups a UV initiator may be included to allow the curable composition to be UV cured.

58. The cured coating should be sufficiently thick enough to fill the gaps between the bond surfaces, but not so thick that the asperities on the electrical bond surface cannot cut through the coating. In one or more embodiments, the cured coating may be characterized by the coatings thickness.

59. In one or more embodiments, the thickness of the cured coating is at least 1 m, in other embodiments at least 3 nm, in other embodiments at least 5 nm, in other embodiments at least 7 nm, and in other embodiments at least 10 nm In one or more embodiments, the thickness of the cured coating is at most 3000 nm, in other embodiments at most 2000 nm, in other embodiments at most 2000 nm, in other embodiments at most 2500 nm, in other embodiments at most 1000 nm, in other embodiments at most 500 nm, in other embodiments at most 100 nm, in other embodiments at most 50 nm, in other embodiments at most 45 nm, in other embodiments at most 40 nm, in other embodiments at most 35 nm, and in other embodiments at most 30 nm.

60. In one or more embodiments, the cured coating composition is self-healing. In these or other embodiments, the cured coating may be repeatedly penetrated by the asperities of the electrical bond surface several times without showing any wear.

61. In one or more embodiments, the cured coating composition is not a fluid at room temperature (20 C-25 C). In these or other embodiments, the cured coating composition of a stabilized electrical bond does not flow or leak when the bond surfaces are connected and disconnected.

62. In one or more embodiments, the cured coating composition is a gel.

63. In one or more embodiments, the cured coating composition may decrease the electronic noise. Those skilled in the art recognize electronic noise as unwanted disturbances superposed on a useful signal that tend to obscure its information content. In one or more embodiments, the stabilized electrical bond shows reduced noise when compared to an unstabilized bond.

64. While particular embodiments of the invention have been disclosed in detail herein, it should be appreciated that the invention is not limited thereto or thereby inasmuch as variations on the invention herein will be readily appreciated by those of ordinary skill in the art. The scope of the invention shall be appreciated from the claims that follow.

Claims

PATENT CLAIMSl claim:
1. A chemical structure comprising:
A cannabinoid molecule of the family listed in Claim 29 below, any of the quantum electronic tunnelling embodiments listed above, and a second cannabinoid molecule of the family listed in Claim 29 below.
2. The chemical structure of any of the preceding claims, where telechelic polypropylene glycol-polyethylene glycol multi-block polymer is selected from the group consisting of diacrylate polypropylene glycol-block-polyethylene glycols, dimethacrylate polypropylene glycol-block-polyethylene glycols, diacrylate polypropylene glycol-block- polyethylene glycol-block-polypropylene glycols, dimethacrylate polypropylene glycol-block-polyethylene glycol-block-polypropylene glycols, diacrylate polyethylene glycol- block-polypropylene glycol-block-polyethylene glycols, dimethacrylate polyethylene glycol-block-polypropylene glycol-block-polyethylene glycols, diacrylate polypropylene glycol-block-polyethylene glycol-block-polypropylene glycol-block-polyethylene glycols, dimethacrylate polypropylene glycol-block-polyethylene glycol-block-polypropylene glycol-block-polyethylene glycols, diacrylate polyethylene glycol-block-polypropylene glycol-block-polyethylene glycol-block-polypropylene glycols, dimethacrylate polyethylene glycol-block-polypropylene glycol-block-polyethylene glycol-block- polypropylene glycols, and combinations thereof.
3. The chemical structure of any of the preceding claims, where the telechelic polypropylene glycol-polyethylene glycol multi-block polymer is defined by the formula:

where each R1 is a hydrogen or a methyl group, x is from about 5 to about 30 y is from about 5 to about 30, and z is from about 5 to about 30.
4. The chemical structure of any of the preceding claims, where the telechelic polypropylene glycol-polyethylene glycol multi-block polymer is defined by the formula:
where each R1 is a hydrogen or a methyl group, x is from about 5 to about 30 y is from about 5 to about 30, and z is from about 5 to about 30.
5. The chemical structure of any of the preceding claims, where the coating further includes the cured product of a reactive diluent.
6. The chemical structure of any of the preceding claims, where the reactive diluent is a telechelic polyethylene glycol oligomers or a mono-functional polyethylene glycol oligomers.
7. The chemical structure of any of the preceding claims, where the reactive diluent is a poly(ethylene glycol) diacrylate or poly(ethylene glycol) dimethacrylate defined by the following formula where each R1 is a hydrogen or a methyl group and n is from about 5 to about 9.
8. The chemical structure of any of the preceding claims, where the reactive diluent is a poly(ethylene glycol) methyl ether acrylate or poly(ethylene glycol) methyl ether methacrylate defined by the following formula where R.1 is a hydrogen or a methyl group and n is from about 5 to about 9.
9. The chemical structure of any of the preceding claims, where the coating further includes a wetting agent.
10. The chemical structure of any of the preceding claims, where the coating further includes a photoinitiator.
11. The chemical structure of any of the preceding claims, where the coating is a gel.

12. The chemical structure of any of the preceding claimsõ where the telechelic polypropylene glycol-block-polyethylene glycol-block-polypropylene glycol polymer has a number average molecular weight of about 2500 to about 3000 g/mol.
13. The chemical structure of any of the preceding claims, where the coating has a thickness from about lnm to about 3000 nm.
14. The chemical structure of any of the preceding claims, where the coating is self- healing.
15. The chemical structure of any of the preceding claims, where the first contact surface and the second contact surface are each independently made from a metal selected from gold, silver, copper, and combinations thereof.
16. The chemical structure of any of the preceding claims, where the chemical structure is selected from electrical connectors, relays, switches, potentiometers, and faders.
17. A method of stabilizing a chemical structure comprising:
Providing a chemical structure that includes a first contact surface and second contact surface; coating at least one of the first or second contact surfaces with a curable chemical composition that includes a telechelic polypropylene glycol -polyethylene glycol multi- block polymer; and curing the curable chemical composition.
18. The method of any of the preceding claims, where the curable chemical composition includes a photoiniator, and the step of curing the curable chemical composition is performed by irradiating the curable chemical composition with UV light.
19. The method of any of the preceding claims, where the telechelic polypropylene glycol¨polyethylene glycol multi-block polymer is selected from the group consisting of diacrylate polypropylene glycol-block-polyethylene glycols, dimethacrylate polypropylene glycol-block-polyethylene glycols, diacrylate polypropylene glycol-block-polyethylene glycol-block-polypropylene glycols, dimethacrylate polypropylene glycol-block- polyethylene glycol-block-polypropylene glycols, diacrylate polyethylene glycol-block- polypropylene glycol-block-polyethylene glycols, dimethacrylate polyethylene glycol- block-polypropylene glycol-block-polyethylene glycols, diacrylate polypropylene glycol- block-polyethylene glycol-block-polypropylene glycol-block-polyethylene glycols, dimethacrylate polypropylene glycol-block-polyethylene glycol-block-polypropylene glycol-block-polyethylene glycols, diacrylate polyethylene glycol-block-polypropylene glycol-block-polyethylene glycol-block-polypropylene glycols, dimethacrylate polyethylene glycol-block-polypropylene glycol-block-polyethylene glycol-block- polypropylene glycols, and combinations thereof.
20. The method of any of the preceding claims, where the telechelic polypropylene glycol-polyethylene glycol multi-block polymer is defined by the formula:
where each R1 is a hydrogen or a methyl group, x is from about 5 to about 30 y is from about 5 to about 30, and z is from about 5 to about 30.
21. The method of any of the preceding claims, where the telechelic polypropylene glycol-polyethylene glycol multi-block polymer is defined by the formula:
where each R1 is a hydrogen or a methyl group, x is from about 5 to about 30 y is from about 5 to about 30, and z is from about 5 to about 30.
22. The method of any of the preceding claims, where the curable chemical composition further includes a reactive diluent.

23. The method of any of the preceding claims, where the reactive diluent is a telechelic polyethylene glycol oligomers or a mono-functional polyethylene glycol oligomers.
24. The method of any of the preceding claims, where the reactive diluent is a poly(ethylene glycol) diacrylate or poly(ethylene glycol) dimethacrylate defined by the following formula where each R1 is a hydrogen or a methyl group and n is from about 5 to about 9.
25. The method of any of the preceding claims, where the reactive diluent is a poly(ethylene glycol) methyl ether acrylate or poly(ethylene glycol) methyl ether methacrylate defined by the following formula where R.1 is a hydrogen or a methyl group and n is from about 5 to about 9.
26. The method of any of the preceding claims, where the curable chemical composition further includes a wetting agent.

27. The method of any of the preceding claims, where the curable chemical composition is solvent free or essentially solvent free.
28. The method of any of the preceding claims, where the step of curing the curable chemical composition results in a cured coating composition in the form of a gel.
29. The method of any of the preceding claims, where the end-of-chain units are any of the following cannabinoid molecules, each of which taken together with the molecules of any of the preceding claims forms a CPC
combinate.
30. The particular design of the CPC molecular shape, causing an electric-field-energized response of the CPC molecule, in which the electric field of the ions in the axon trigger the molecule to rotate to an orientation with the lowest drag coefficient, thereby targeting the cannabinoid end of the CPC
molecule to mate with the receptors on the dendrite.
31. The design of 30 results the PPPDI molecular section to be positioned in the middle of the synapse, where it communicates quantum electronically with both axon and dendrite, passing an electrical signal between both. Depending on the particular cannabinoid of Claim 29, that signal may be in the forward (axon-dendrite) or reverse (dendrite-axon) direction. This orientation and positioning is critical to the electrical and receptor-enabled operation of the CPC molecule.
REFERENCES
1 "Sativex (Cannabidiol/Tetrahydrocannabinol) Bayer Label" (PDF).
bayer.ca. Retrieved June 28, 2018.
2 Jump up to: a b cd e "Epidiolex (Cannabidiol) FDA Label" (PDF). fda.gov.
Retrieved June 28, 2018. For label updates see FDA index page for 3 ^ "cannabidiol (CHEBI:69478)". www.ebi.ac.uk.
4 ^ Jump up to: a b Mechoulam R, Parker LA, Gallily R (November 2002).
"Cannabidiol: an overview of some pharmacological aspects". Journal of Clinical Pharmacology. 42 (11 Suppl): 11S-19S.
clod 0.1002/.1552-4604.2002.tb05998.x. PMID 12412831.
^ Jump up to: a b Scuderi C, Filippis DD, luvone T, Blasio A, Steardo A, Esposito G (May 2009). "Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders". Phytotherapy Research (Review). 23 (5): 597-602. doi:10.1002/ptr.2625. PMID 18844286.

6 ^ Jump up to: a b c Devinsky, Orrin; Cilio, Maria Roberta; Cross, Helen;
Fernandez-Ruiz, Javier; French, Jacqueline; Hill, Charlotte; Katz, Russell; Di Marzo, Vincenzo; Jutras-Aswad, Didier; Notcutt, William George; Martinez-Orgado, Jose; Robson, Philip J.; Rohrback, Brian G.; Thiele, Elizabeth; Whalley, Benjamin; Friedman, Daniel (May 22, 2014). "Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders". Epilepsia. 55 (6):
791-802. doi:10.1111/epi.12631. PMC 4707667. PMID 24854329.
7 ^ Jump up to: a b c Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimar es FS (December 2012). "Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences (Review). 367 (1607): 3364-78. doi:10.1098/rstb.2011.0389. PMC 3481531. PMID 23108553.
8 ^Jump up to: a b "I Boggs, Douglas L; Nguyen, Jacques D; Morgenson, Daralyn; Taffe, Michael A; Ranganathan, Mohini (September 6, 2017). "Clinical and preclinical evidence for functional interactions of cannabidiol and .DELTA.9-tetrahydrocannabinol".
Neuropsychopharmacology. 43 (1): 142-154.
doi:10.1038/npp.2017.209. ISSN 0893-133X. PMC 5719112.
PMID 28875990.
9 ^ Jump up to: a b cd Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M (July 2017). "Cannabidiol: State of the art and new challenges for therapeutic applications". Pharmacol. Ther. 175:
133-150. doi:10.1016/j.pharmthera.2017.02.041. PMID 28232276.
^ Jump up to: a b c Iseger TA, Bossong MG (March 2015). "A
systematic review of the antipsychotic properties of cannabidiol in humans". Schizophrenia Research. 162 (1-3): 153-61.
doi:10.1016/j.schres.2015.01.033. PMID 25667194.
11 ^ A Aizpurua-Olaizola O, Soydaner U, Öztürk E, Schibano D, Simsir Y, Navarro P, Etxebarria N, Usobiaga A (February 2016). "Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes". Journal of Natural Products. 79 (2): 324-31. doi:10.1021/acs.jnatprod.5b00949.
PMID 26836472.
12 ^ Jump up to: a b c "FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy". US Food and Drug Administration. June 25, 2018.
Retrieved June 25, 2018.

13 ^ A Jump up to: a b c d "DEA reschedules Epidiolex, marijuana-derived drug, paving the way for it to hit the market". CNBC. September 27, 2018.
14 " Conaway, K. Michael (December 20, 2018). "Text - H.R.2 - 115th Congress (2017-2018): Agriculture Improvement Act of 2018".
www.congress.gov. Retrieved May 1, 2019.
15 ^ "FDA Regulation of Cannabis and Cannabis-Derived Products:
Questions and Answers". US Food and Drug Administration. April 2, 2019. Retrieved May 18, 2019.
16 " Jump up to: a b Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, Herkes GK, Farrell M, Degenhardt L (July 2018).
"Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence". J. Neurol.
Neurosurg. Psychiatry. 89 (7): 741-753. doi:10.1136/jnnp-2017-317168. PMID 29511052.
17 ^ Silva TB, Balbino CQ, Weiber AF (May 1, 2015). "The relationship between cannabidiol and psychosis: A review". Annals of Clinical Psychiatry. 27 (2): 134-41. PMID 25954940.
18 ^ Jump up to: a b Blessing EM, Steenkamp MM, Manzanares J, Marmar CR (October 2015). "Cannabidiol as a Potential Treatment for Anxiety Disorders". Neurotherapeutics. 12 (4): 825-36.
doi:10.1007/s13311-015-0387-1. PMC 4604171. PMID 26341731.
19 ^ Jump up to: a b Prud'homme M, Cata R, Jutras-Aswad D (2015).
"Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence". Substance Abuse. 9: 33-8.
doi:10.4137/SART.S25081. PMC 4444130. PMID 26056464.
20 ^ A Fernández-Ruiz J, Sagredo O, Pazos MR, Garcia C, Pertwee R, Mechoulam R, Martinez-Orgado J (February 2013). "Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?". British Journal of Clinical Pharmacology. 75 (2): 323-33. doi:10.1111/j.1365-2125.2012.04341.x. PMC 3579248.
PMID 22625422.
21 ^ A Fischer B, Russell C, Sabioni P, van den Brink W, Le Foll B, Hall W, Rehm J, Room R (August 2017). "Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations". American Journal of Public Health. 107 (8): e1-e12. doi:10.2105/AJPH.2017.303818. PMID 28644037.
22 ^ Iffland K, Grotenhermen F (2017). "An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies". Cannabis and Cannabinoid Research. 2 (1): 139-154. doi:10.1089/can.2016.0034. PMC 5569602. PMID 28861514.
23 ^ Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ (August 1995).
"Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain". Drug Metabolism and Disposition. 23 (8): 825-831. PMID 7493549.
24 ^ Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T, Gunasekaran N, Karl T, Long LE, Huang XF, Liu K, Arnold JC, McGregor IS (November 2011). "Cannabidiol potentiates .DELTA.9-tetrahydrocannabinol (THC) behavioural effects and alters THC
pharmacokinetics during acute and chronic treatment in adolescent rats". Psychopharmacology. 218 (2): 443-457. doi:10.1007/s00213-011-2342-0. PMID 21667074.
25 ^ Ghovanloo MR, Shuart NG, Mezeyova M, Dean RA, Ruben PC, Goodchild SJ (September 2018). "Inhibitory effects of cannabidiol on voltage-dependent sodium currents". Journal of Biological Chemistry.
293 (43): 16546-16558. doi:10.1074/jbc.RA118.004929.
PMC 6204917. PMID 30219789.
26 ^ Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM, Stadelmann AM (December 2005). "Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract". Ther Drug Monit. 27 (6): 799-810. doi:10.1097/01.ftd.0000177223.19294.5c.
PMID 16306858.
27 ^ Lucas, Catherine J.; Galettis, Peter; Schneider, Jennifer (November 2018). "The pharmacokinetics and the pharmacodynamics of cannabinoids: The pharmacokinetics and the pharmacodynamics of cannabinoids". British Journal of Clinical Pharmacology. 84 (11):
2477-2482. doi:10.1111/bcp.13710. PMC 6177698. PM ID 30001569.
28 ^ Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO (August 2007). "Cannabidiol--recent advances". Chemistry & Biodiversity (Review). 4 (8): 1678-92. doi:10.1002/cbdv.200790147.
PMID 17712814.
29 ^ Jump up to: a b Pertwee RG (January 2008). "The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin". British Journal of Pharmacology. 153 (2):
199-215. doi:10.1038/sj.bjp.0707442. PMC 2219532.
PMID 17828291.

30 ^ Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (December 2007). "The orphan receptor GPR55 is a novel cannabinoid receptor".
British Journal of Pharmacology. 152 (7): 1092-101.
doi:10.1038/sj.bjp.0707460. PMC 2095107. PMID 17876302.
31 ^ Laun AS, Shrader SH, Brown KJ, Song ZH (June 2018). "GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol". Acta Pharmacol. Sin. 40 (3): 300-308. doi:10.1038/s41401-018-0031-9. PMID 29941868.
32 ^ Russo EB, Burnett A, Hall B, Parker KK (August 2005). "Agonistic properties of cannabidiol at 5-HT1a receptors". Neurochemical Research. 30 (8): 1037-43. doi:10.1007/s11064-005-6978-1.
PMID 16258853.
33 ^ Kathmann M, Flau K, Redmer A, Trankle C, Schlicker E (February 2006). "Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 372 (5): 354-61. doi:10.1007/s00210-006-0033-x. PMID 16489449.
34 ^ Russo, E. B. (2008). "Cannabinoids in the management of difficult to treat pain". Therapeutics and Clinical Risk Management. 4 (1):
245-259. doi:10.2147/TCRM.S1928. PMC 2503660.
PMID 18728714.
35 ^ "Sativex Oromucosal Spray". Medsafe, New Zealand Medicines and Medical Devices Safety Authority. December 19, 2018. Retrieved April 3, 2019.
36 ^ Jones PG, Falvello L, Kennard O, Sheldrick GM, Mechoulam R
(1977). "Cannabidiol". Acta Crystallogr. B. 33 (10): 3211-3214.
doi:10.1107/S0567740877010577.
37 ^ Mechoulam R, Ben-Zvi Z, Gaoni Y (August 1968). "Hashish--13. On the nature of the Beam test". Tetrahedron. 24 (16): 5615-24.
doi:10.1016/0040-4020(68)88159-1. PMID 5732891.
38 ^ Gaoni Y, Mechoulam R (1966). "Hashish-VII The isomerization of cannabidiol to tetrahydrocannabinols". Tetrahedron. 22 (4): 1481-1488. doi:10.1016/S0040-4020(01)99446-3.
39 A Kuppers, F.J.E.M.; Bercht, C.A.L.; Salemink, C.A.; Lousberg, R.J.J.Ch., Terlouw, J.K.; Heerma, W. (1975), "Cannabis-XV:
Pyrolysis of cannabidiol. Structure elucidation of four pyrolytic products", Tetrahedron, 31 (13-14): 1513-1516, doi:10.1016/0040-4020(75)87002-5 40 ^ Petrzilka T, Haefliger W, Sikemeier C, Ohloff G, Eschenmoser A
(March 1967). "[Synthesis and optical rotation of the (-)-cannabidiols]". Helvetica Chimica Acta. 50 (2): 719-23.
doi:10.1002/hIca.19670500235. PMID 5587099.
41 ^ Gaoni Y, Mechoulam R (1985). "Boron trifluoride etherate on alumuna - a modified Lewis acid reagent. An improved synthesis of cannabidiol". Tetrahedron Letters. 26 (8): 1083-1086.
doi:10.1016/S0040-4039(00)98518-6.
42 ^ Kobayashi Y, Takeuchi A, Wang YG (June 2006). "Synthesis of cannabidiols via alkenylation of cyclohexenyl monoacetate". Organic Letters. 8 (13): 2699-702. doi:10.1021/ol060692h. PMID 16774235.
43 ^ Taura F, Sirikantaramas S, Shoyama Y, Yoshikai K, Shoyama Y, Morimoto S (June 2007). "Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativa".
FEBS Letters. 581 (16): 2929-34. doi:10.1016/j.febslet.2007.05.043.
PMID 17544411.
44 ^ Marks MD, Tian L, Wenger JP, Omburo SN, Soto-Fuentes W, He J, Gang DR, Weiblen GD, Dixon RA (2009). "Identification of candidate genes affecting Delta9-tetrahydrocannabinol biosynthesis in Cannabis sativa". Journal of Experimental Botany. 60 (13): 3715-26.
doi:10.1093/jxb/erp210. PMC 2736886. PMID 19581347.
45 ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 30 (2): 241. 2016.
46 ^ "Billboard featuring hemp leaf raises questions about new beverage for sale in Cincinnati I WLWT5". WLWT5. September 29, 2017.
Retrieved September 29, 2017.
47 ^ "CBD-Infused Foods Becoming a New Health Trend and Penetrating the Market". Retrieved December 14, 2017.
48 ^ "Warning Letters and Test Results for Cannabidiol-Related Products". Food and Drug Administration. November 2, 2017.
Retrieved January 2, 2018.
49 ^ Fox A, Ravitz JR, Leongini EM, Brian J M. "Companies Marketing CBD Products Be Warned: FDA Is Watching". Lexology. Retrieved December 14, 2017.
50 ^ Angelica LaVito, Thomas Franck (February 15, 2019). "New York City plans to fine restaurants using CBD in food and drinks". CNBC.
Retrieved February 19, 2019.
51 ^ Romney L (September 13, 2012). "On the frontier of medical pot to treat boy's epilepsy". Los Angeles Times.
52 ^ Sachs J, McGlade E, Yurgelun-Todd D (October 2015). "Safety and Toxicology of Cannabinoids". Neurotherapeutics. 12 (4): 735-46.
doi:10.1007/s13311-015-0380-8. PMC 4604177. PMID 26269228.

53 ^ lzzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R (October 2009). "Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb". Trends in Pharmacological Sciences. 30 (10): 515-27. doi:10.1016/j.tips.2009.07.006.
PMID 19729208.
54 ^ Jump up to: a b "Industrial hemp". Department of Agriculture, State of Colorado. 2018. Retrieved September 14, 2018.
55 ^ Angell T (August 13, 2018). "UN Launches First-Ever Full Review Of Marijuana's Status Under International Law". Marijuana Moment.
Retrieved November 1, 2018.
56 ^ "Poisons Standard June 2017". Legislation.gov.au. Retrieved December 4, 2016.
57 ^ "Health products containing cannabis or for use with cannabis:
Guidance for the Cannabis Act, the Food and Drugs Act, and related regulations". Government of Canada. July 11, 2018. Retrieved October 19, 2018.
58 ^ Communications, Government of Canada, Department of Justice, Electronic. "Cannabis Legalization and Regulation".
www.justice.gc.ca.
59 ^ Jump up to: a b c d Will Chu (January 31, 2019). "Updated EC ruling for CBD classes supplement ingredient as Novel Food".
NutraIngredients.com, William Reed Business Media Ltd. Retrieved January 1, 2019.
60 ^ "Cannabinoids, searched in the EU Novel food catalogue (v.1.1)".
European Commission. January 1, 2019. Retrieved February 1, 2019.
61 ^ Jump up to: a b "CosIng - Cosmetics - Cannabidiol". European Commission. Retrieved December 4, 2016.
62 ^ Fournier G, Beherec O, Bertucelli S (2003). "Intérêt du rapport .DELTA.-9-THC / CBD dans le contrôle des cultures de chanvre industriel" [The advantage of the .DELTA.-9-THC / CBD ratio in the control of industrial hemp crops]. Annales de Toxicologie Analytique (in French). 15 (4):
250-59. doi:10.1051/ata/2003003.
63 ^ "CBD products should follow the drug laws". Swedish Medical Products Agency. April 4, 2018. Retrieved July 31, 2018.
64 ^ "Doctors now able to prescribe cannabidiol". radionz.co.nz.
Retrieved June 2, 2017.
65 ^ "CBD products". www.health.govt.nz. Retrieved March 10, 2019.
66 ^ "Sativex Oromucosal Spray - Summary of Product Characteristics (SPC)". Medicines.org.uk (eMC). Retrieved December 4, 2016.

67 ^ "MHRA statement on products containing Cannabidiol (CBD)".
Gov.uk. December 14, 2016.
68 ^ "What are the rules about cannabis oil in the UK?". BBC News -Health. July 26, 2018. Retrieved February 8, 2019.
69 ^ Gunn L, Haigh L (January 29, 2019). "British watchdog deems CBD
a novel food, seeks to curtail sale on UK market". Nutrition Insight, CNS Media BV. Retrieved January 1, 2019.
70 ^ Jump up to: a b c Jann Bellamy (May 9, 2019). "FDA: No CBD in dietary supplements or foods for now, but let's talk". Science-Based Medicine.
71 ^ "Epilepsy Foundation Statement on DEA's Scheduling of Epidiolex"
(Press release). Landover, MD: Epilepsy Foundation. September 27, 2018. Retrieved November 1, 2018.
72 ^ "State Rescheduling for FDA-approved Therapies Derived from CBD". Epilepsy Foundation. Retrieved November 1, 2018.
73 ^ Maa E, Figi P (June 2014). "The case for medical marijuana in epilepsy". Epilepsia. 55 (6): 783-86. doi:10.1111/epi.12610.
PMID 24854149.
74 ^ Young S. "Marijuana stops child's severe seizures". CNN. Retrieved May 14, 2018.
75 ^ Jump up to: a b c "State Medical Marijuana Laws". National Conference of State Legislatures. April 27, 2018. Retrieved May 14, 2018.
76 ^ "FDA and Marijuana: Questions and Answers. No. 12 - Can products that contain THC or cannabidiol (CBD) be sold as dietary supplements?". US Food and Drug Administration. December 20, 2018. Retrieved January 13, 2019.
77 ^ Stephen Daniells (November 6, 2018). "Top FDA official: 'Anyone who thinks CBD is lawful is mistaken". Nutralngredients-USA, William Reed Business Media Ltd. Retrieved November 6, 2018.
78 ^ Corba, Jacqueline. "Super Bowl Champ: CBD Can Solve NFL's Opioid Problem". Cheddar. Retrieved January 29, 2019.
79 ^ Summers DJ (March 22, 2017). "Is CBD Oil Legal? Depends on Where You Are and Who You Ask". Leafly. Retrieved January 3, 2018.
80 ^ Gaines LV (March 23, 2017). "Why are CBD products sold over the counter some places and tightly regulated in others?". Chicago Reader. Retrieved January 3, 2018.
81 ^ "The 2014 Farm Bill". thefarmbill.com. Retrieved November 27, 2018.

82 ^ "7 U.S. Code ~ 5940 - Legitimacy of industrial hemp research". LII /
Legal Information Institute. Retrieved November 27, 2018.
83 ^ Zhang, Mona. "No, CBD Is Not 'Legal in All 50 States". Forbes.
Retrieved November 27, 2018.
84 ^ "Trump just signed a law that could spark a boom for the $1 billion marijuana-linked CBD industry". Business Insider. December 20, 2018. Retrieved January 29, 2019.
85 ^ Estevez, Lauren. "Guide to CBD Laws". LME Law. Retrieved January 29, 2019.
^ "Cannabis a faible teneur en THC et CBD" (in French). BAG.Admin.ch.
Retrieved May 20, 2017.